Login
Companies $INCY
$116.74 -$3.53 (2.93%) After hours
INCYTE CORP logo

INCYTE CORP

incyte.com

What Do They Do?

Sells prescription medicines to pharmacies, distributors and wholesalers for blood cancers, other cancers, and inflammatory and autoimmune diseases.

How Do They Make Money?

Most revenue comes from selling medicines to pharmacies, distributors and wholesalers; sales count when customers receive the products. Incyte also earns royalties on partners’ sales and license or milestone payments through collaborations, with milestone revenue counted when the milestone is achieved.

revenue
SegmentShareRevenue
Product revenues, net
Sold outright

85%
FY2022: 81%
Product royalty revenues
Licensed

12%
FY2022: 14%
Milestone and contract revenues
2.9%
FY2022: 4.9%

Who Are Their Customers?

In the United States, Incyte sells to specialty and retail pharmacies, specialty distributors and wholesalers; in Europe and some other markets, it sells to retail and hospital pharmacies and distributors. PEMAZYRE sales in Japan go to an exclusive wholesaler.

Do Revenues Turn Into Profits?

Yes. It kept 25 cents of every revenue dollar as net income in FY2025 and turned 26 cents into free cash flow.

Operating income, FY2025
29% of revenue
▲ +2369% vs FY2024 ($61.4M, 1%)
Net income, FY2025
25% of revenue
▲ +3845% vs FY2024 ($32.6M, 1%)
Free cash flow, FY2025
26% of revenue
▲ +444% vs FY2024 ($249.1M, 6%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +14%
vs $1.4B in Q3 FY2025
Net income
▼ Turned to a loss
vs $424.2M in Q3 FY2025
Net sales share of revenue vs 84.2% in Q3 FY2025
  • Jul 6, 2026 Acquired Vega Therapeutics, adding a bleeding-disorder drug candidate. VGA039 is an investigational antibody in Phase 3 development for von Willebrand disease.

Growing. Revenue grew 73% in 4 years, from $3B in FY2021 to $5.2B in FY2025, about 15% a year.

Tafasitamab rights In the older report, Incyte co-commercialized tafasitamab in the United States with MorphoSys and held exclusive rights outside the United States; the latest report says it holds exclusive global rights after buying the rights from MorphoSys.

Revenue over time
Product revenues, net Product royalty revenues Milestone and contract revenues
$10B$5B$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support